← Search & browse all drugs
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES › Other cytotoxic antibiotics
plicamycin
L01DC02
Forms & Strengths
- Vial for injection: 2.5mg
- Powder for solution: 2.5mg
Adult Dosing
- Test dose: 0.25mg IV
- Typical dose: 2.5mg IV q1-4wks
- Max dose: 30mcg/kg or 2.5mg IV
Pediatric Dosing
- Safety and efficacy not established in pediatric patients
Indications
- Testicular cancer
- Hyperviscosity syndrome in myeloma
- Hypercalcemia of malignancy
Mechanism of Action
- Binds to DNA, inhibiting RNA synthesis
- Interferes with cell division, inducing apoptosis
Contraindications
- Hypersensitivity to plicamycin
- Severe renal impairment
- Pregnancy
Adverse Reactions
- Myelosuppression
- Nephrotoxicity
- Thrombocytopenia
- Leukopenia
- Hypocalcemia
- Gastrointestinal disturbances
- Hypotension
Drug Interactions
- Nephrotoxic drugs, increase risk of nephrotoxicity
- Myelosuppressive agents, increase risk of myelosuppression
- Digoxin, may potentiate hypocalcemia
Curated Content: Needs Vetting Before Put to Clinical Use